Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marinus ( (MRNS) ) has issued an announcement.
Marinus Pharmaceuticals has terminated its agreements with Orion Corporation, including collaboration and supply agreements, as part of its strategic review. The termination includes a mutual release of claims, and Marinus will pay Orion €1.5 million under certain conditions, while Orion is relieved from a €500,000 payment previously due.
More about Marinus
Marinus Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics. The company’s primary focus includes products incorporating ganaxolone, used for various medical indications.
YTD Price Performance: -96.59%
Average Trading Volume: 2,769,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.5M
See more data about MRNS stock on TipRanks’ Stock Analysis page.